Russia's St Petersburg to attract global drugmakers to establish production

12 January 2021

The authorities of St Petersburg, one of the main centers of pharmaceutical production in Russia, plan to create additional conditions to attract foreign drugmakers to the region, according to press-service of the St Petersburg regional government and local pharma analysts.

For this purpose, a new mechanism for attracting investments in the pharmaceutical sector of the city was designed and involves the use of so-called offset contracts. That scheme involves signing long-term contracts on the supplies of drugs for the needs of the city in exchange of localization of production, reports The Pharma Letter’s local correspondent.

Minimum 1 billion roubles investment to qualify

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK